OptiBiotix confirms first LPLDL sales to Germany

Life sciences business OptiBiotix Health announced on Tuesday that it agreed to supply 100,000 units of its ‘LPLDL’ product to German company HLH BioPharma Vertriebs.

The AIM-traded firm said HLH has more than 20 years of experience in the distribution of probiotic and natural products under the brand names ‘Lactobact’ and ‘Casa Sana’, and remained one of Europe's leading suppliers of probiotics to the pharmacy market.

It said ‘LPLDL’ would be supplied as bulk capsules, which would be packaged and branded as part of HLH's ‘Lactobact’ brand.

The pre-launch sale provided “moderate” levels of early income, the board said, and reflected the high level of industry awareness in ‘LPLDL’ as a functional component in a wide range of consumer healthcare and pharmaceutical products.

It said the sales order was the first step in a business to business strategy of bringing OptiBiotix's science together with a partner's national brand portfolio and market presence to serve multiple consumer healthcare and pharmaceutical markets around the world.

“We are pleased to announce the supply of ‘LPLDL’ to HLH which will be sold as part of its market leading ‘Lactobact’ brand,” said OptiBiotix CEO Stephen O'Hara.

“We see this as the first step in building sales and market presence of ‘LPLDL’ as the 'intel' inside a wide range of products for cardiovascular health across both consumer and pharmaceutical markets around the world.

“This creates the opportunity for multiple revenue streams from sales of the strain, white label, and branded products in different presentations and formulations to meet the needs of a diverse range of national and international markets.”